GPC3 AND ASGPR1 DOUBLE-TARGETED TRANSGENIC IMMUNE EFFECTOR CELL AND USE THEREOF

• 收藏
• 分享

专利权人:

Carsgen Therapeutics Ltd

发明人:

HUAMAO WANG,Xiumei Cai,Hongxia Zhao,Bo Song,Yuanmei Chen,Yinyu Zhu

申请号：

US15532965

公开号：

US20180201902A1

申请日:

2015.11.30

申请国别(地区):

US

年份:

2018

代理人:

摘要：

Provided are a GPC3 and ASGPR1 double-targeted transgenic immune effector cell and use thereof. The cell is an immune effector cell capable of identifying the gene modification of GPC3 and ASGPR1 simultaneously, and the cell can be used in the treatment of GPC3 and ASGPR1 double positive tumours, such as liver cancer.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/